Quince Therapeutics, Inc. quarterly report, Q1 FY2021

Business context and reporting period

Entity discrepancy: The request identifies Quince Therapeutics, Inc., but the supplied Form 10-Q is for Cortexyme, Inc. (Nasdaq: CRTX), for the quarter ended March 31, 2021. This summary reflects the filing text.

Cortexyme is a clinical-stage biopharmaceutical company developing atuzaginstat (COR388) for Alzheimer’s disease and other gingipain-inhibitor programs. It reported no product revenue.

Financial results and liquidity

Amounts below are in U.S. dollars; financial statement amounts are converted from thousands to millions where appropriate.

Profitability and operating margins are not meaningful because the company had no revenue. At March 31, 2021, cash and cash equivalents were $85.3 million, short-term investments $61.7 million, and long-term investments $23.7 million; total cash, cash equivalents, and investments were approximately $170.8 million. Current liabilities were $17.9 million, total liabilities $18.0 million, and stockholders’ equity $156.5 million. The balance sheet reports no borrowings; lease liabilities were $0.4 million, including current and long-term operating lease liabilities.

Material changes versus the prior comparable period

• Net loss increased $5.9 million, or 34.4%; operating expenses rose $5.5 million, or 30.5%.
• R&D expense increased 17.0%, despite atuzaginstat direct costs falling $2.7 million. New COR588 IND-enabling work added $1.4 million, while personnel-related R&D costs rose $3.6 million, including higher stock-based compensation.
• G&A expense rose 86.6%, primarily reflecting increased headcount and $2.4 million of additional allocated stock-based compensation.
• Stock-based compensation increased to $7.0 million from $2.0 million. Interest income fell to $0.2 million from $0.7 million.
• Operating cash use increased to $13.6 million from $10.8 million. Investing activities provided $31.6 million, principally from investment maturities; financing provided $0.4 million, versus $117.9 million in Q1 2020, which included the PIPE financing.

Outlook, management commentary, and risks

• Management expected topline results from the fully enrolled 643-participant GAIN Phase 2/3 Alzheimer’s trial in Q4 2021, with REPAIR periodontal substudy results also expected in Q4. Management said a December 2020 interim analysis was successful, but this filing does not provide detailed results.
• On February 12, 2021, the FDA placed a partial clinical hold on the atuzaginstat open-label extension after review of hepatic adverse events. No new OLE participants could enroll and existing participants were to discontinue; participants in the blinded, placebo-controlled GAIN phase continued treatment. The reported hepatic events were described as reversible, without known long-term adverse effects.
• Management expected COR588’s first-in-human study to begin in Q3 2021 and first patient enrollment in the PEAK Parkinson’s study in Q3 2021. These are forward-looking expectations, not reported outcomes.
• Management stated that existing cash, cash equivalents, and investments were expected to fund planned operations through 2023, including completion and announcement of GAIN topline results. The liquidity note separately states that cash, cash equivalents, and short-term investments would fund planned operations for at least 12 months from issuance of the statements. The filing warns that spending, trial outcomes, regulatory requirements, and access to additional capital could change the runway.
• COVID-19 had not materially disrupted operations or changed stated GAIN timelines as of the filing, but could affect trials, suppliers, and costs. Other key risks include clinical efficacy and safety uncertainty, regulatory approval, manufacturing and vendor dependence, competition, intellectual property protection, and potential future financing and dilution.
• No material legal proceedings or off-balance-sheet arrangements were reported. The company reported effective disclosure controls and no material change in internal control over financial reporting during the quarter.

Important facts for investors to verify

• Confirm the intended issuer: the supplied filing is for Cortexyme, not Quince Therapeutics.
• Check subsequent FDA updates on the OLE hold, hepatic safety findings, and whether the blinded GAIN trial continued as planned.
• Verify actual GAIN enrollment and analysis population: the filing cites 643 participants, but also refers to enrolling an additional 73 subjects to mitigate COVID-related risks.
• Compare subsequent trial readouts and regulatory developments with the Q4 2021 expectations stated here; this filing provides no detailed interim efficacy data.
• Assess cash burn and runway against the differing liquidity disclosures, planned pipeline spending, and any later financing.